Syros Pharmaceuticals, Inc. - common stock (SYRS): Price and Financial Metrics

Syros Pharmaceuticals, Inc. - common stock (SYRS): $6.73

0.05 (+0.75%)

POWR Rating

Component Grades














  • Value is the dimension where SYRS ranks best; there it ranks ahead of 71.15% of US stocks.
  • The strongest trend for SYRS is in Momentum, which has been heading down over the past 179 days.
  • SYRS ranks lowest in Momentum; there it ranks in the 6th percentile.

SYRS Stock Summary

  • SYROS PHARMACEUTICALS INC's market capitalization of $40,575,413 is ahead of merely 12% of US-listed equities.
  • Of note is the ratio of SYROS PHARMACEUTICALS INC's sales and general administrative expense to its total operating expenses; only 7% of US stocks have a lower such ratio.
  • In terms of volatility of its share price, SYRS is more volatile than 98.98% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to SYROS PHARMACEUTICALS INC are AUTL, CNCE, ABUS, ALT, and ALPN.
  • Visit SYRS's SEC page to see the company's official filings. To visit the company's web site, go to

SYRS Valuation Summary

  • SYRS's price/earnings ratio is -0.3; this is 101.53% lower than that of the median Healthcare stock.
  • SYRS's price/earnings ratio has moved up 9.7 over the prior 76 months.

Below are key valuation metrics over time for SYRS.

Stock Date P/S P/B P/E EV/EBIT
SYRS 2022-09-23 1.4 1.1 -0.3 -0.4
SYRS 2022-09-22 1.6 1.3 -0.4 -0.4
SYRS 2022-09-21 1.7 1.4 -0.4 -0.4
SYRS 2022-09-20 1.5 1.3 -0.4 -0.4
SYRS 2022-09-19 1.5 1.2 -0.3 -0.4
SYRS 2022-09-16 1.8 1.5 -0.4 -0.5

SYRS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SYRS has a Quality Grade of C, ranking ahead of 31.76% of graded US stocks.
  • SYRS's asset turnover comes in at 0.093 -- ranking 271st of 682 Pharmaceutical Products stocks.
  • ONVO, OPK, and ICPT are the stocks whose asset turnover ratios are most correlated with SYRS.

The table below shows SYRS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.093 1 -1.040
2021-03-31 0.093 1 -1.148
2020-12-31 0.092 1 -1.221
2020-09-30 0.067 1 -0.971
2020-06-30 0.044 1 -0.838
2020-03-31 0.026 1 -0.889

SYRS Price Target

For more insight on analysts targets of SYRS, see our SYRS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $17.29 Average Broker Recommendation 1.44 (Moderate Buy)

SYRS Stock Price Chart Interactive Chart >

Price chart for SYRS

SYRS Price/Volume Stats

Current price $6.73 52-week high $48.00
Prev. close $6.68 52-week low $5.25
Day low $6.66 Volume 134,200
Day high $6.95 Avg. volume 123,433
50-day MA $7.68 Dividend yield N/A
200-day MA $12.56 Market Cap 42.40M

Syros Pharmaceuticals, Inc. - common stock (SYRS) Company Bio

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing medicines that control genes to transform the lives of patients with cancer, immune-mediated diseases, and other diseases. The company was founded in 2011 and is based in Cambridge, Massachusetts.

SYRS Latest News Stream

Event/Time News Detail
Loading, please wait...

SYRS Latest Social Stream

Loading social stream, please wait...

View Full SYRS Social Stream

Latest SYRS News From Around the Web

Below are the latest news stories about SYROS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate SYRS as an investment opportunity.

Syros Pharmaceuticals, Inc. (SYRS) Upgraded to Buy: What Does It Mean for the Stock?

Syros Pharmaceuticals, Inc. (SYRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | September 23, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Good morning, investor!

William White on InvestorPlace | September 20, 2022

Stocks Choppy As Bitcoin, Crypto Sell Off

Stocks are struggling for direction midday. The Dow Jones Industrial Average was last seen slightly below breakeven, while the S&P 500 Index and the Nasdaq Composite are back in the red. | September 19, 2022

Brookline Capital Markets Remains a Buy on Syros Pharmaceuticals (SYRS)

Brookline Capital Markets analyst Leah R. Cann reiterated a Buy rating on Syros Pharmaceuticals (SYRS - Research Report) today and set a price target of $60.00. The company's shares closed yesterday at $0.73.R. Cann covers the Healthcare sector, focusing on stocks such as Moderna, Kymera Therapeutics, and Syros Pharmaceuticals. According to TipRanks, R. Cann has an average return of -1.6% and a 38.89% success rate on recommended stocks. Currently, the analyst consensus on Syros Pharmaceuticals is a Strong Buy with an average price target of $18.25.See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $5.20 and a one-year low of $0.65.

Carrie Williams on TipRanks | September 17, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

We're starting off the final trading day of the week with a look at the biggest pre-market stock movers for Friday and what's moving them!

William White on InvestorPlace | September 16, 2022

Read More 'SYRS' Stories Here

SYRS Price Returns

1-mo -0.55%
3-mo -23.17%
6-mo -41.48%
1-year -85.31%
3-year -91.88%
5-year -95.80%
YTD -79.36%
2021 -69.95%
2020 57.02%
2019 24.06%
2018 -42.75%
2017 -19.98%

Continue Researching SYRS

Want to see what other sources are saying about Syros Pharmaceuticals Inc's financials and stock price? Try the links below:

Syros Pharmaceuticals Inc (SYRS) Stock Price | Nasdaq
Syros Pharmaceuticals Inc (SYRS) Stock Quote, History and News - Yahoo Finance
Syros Pharmaceuticals Inc (SYRS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5548 seconds.